(Co. Reg. No: 200405621W)

iX BIOPHARMA SECURES CANADIAN PATENT FOR WAFERIX DRUG DELIVERY TECHNOLOGY

Singapore, 31 October 2016 – Homegrown specialty pharmaceutical company **iX Biopharma Ltd.** ("iX Biopharma" or, together with its subsidiaries, "the Group") is pleased to announce that it has been granted a patent in Canada (no. 2777218) for its **WaferiX** drug delivery technology. Canada has a potential market size of C$515 million and C$97 million for opioids and sleep aids, according to Patented Medicine Prices Review Board of Canada and Euromonitor respectively.

The Group has also been granted a patent in South Korea this year, while counterpart patents were granted in Australia, Indonesia, Japan, Malaysia, New Zealand and Singapore prior to that.

The grant of the Canadian patent, which expires on 26 October 2030, marks another milestone for iX Biopharma, following the positive results received in September 2016 from its bioequivalence study for **PheoniX,** a drug for the treatment of male erectile dysfunction.

About iX Biopharma Ltd

iX Biopharma Ltd is a Singapore public-listed specialty pharmaceutical company, with manufacturing and laboratory testing facilities in Australia. The Group is focused on the development and commercialisation of innovative therapies for improving the quality of life of those suffering from pain and other health conditions. The Company leverages its patented sublingual drug delivery technology, **WaferiX**, to develop proprietary products that incorporate pharmacologically active compounds that have been approved by the United States Food and Drug Administration. Its pipeline of products under development includes **Wafermine** and **BnoX** for pain management, **PheoniX** for erectile dysfunction, and **WafeRest** for improved sleep quality.

Contact for media:

Ms Alvina Tan
DID: +65 6221 2123
H/P: +65 9787 7267
Email: alvina.tan@arkadvisors.com.sg

Ms Karin Lai
DID: +65 6221 0081
H/P: +65 9837 8136
Email: karin.lai@arkadvisors.com.sg

This document has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, CIMB Bank Berhad, Singapore Branch, for compliance with the relevant rules of the SGX-ST. CIMB Bank Berhad, Singapore Branch, has not independently verified the contents of this announcement. This document has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr Tony Toh, Director, Investment Banking, CIMB Bank Berhad, Singapore Branch. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.